Inhibrx Biosciences
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
11025 N Torrey Pines Rd Ste 140, La Joll...Phone Number
(858) 795-4220Website
www.inhibrx.comRevenue
<$5 MillionStock Symbol
INBXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Inhibrx Biosciences
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.Explore more
Inhibrx Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Inhibrx Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Inhibrx Biosciences recently announced quarterly report
Inhibrx Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Inhibrx Biosciences had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Inhibrx Biosciences
Funding: Get notified immidiatlly once Inhibrx Biosciences has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Inhibrx Biosciences has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Inhibrx Biosciences launches new products
Website visits: Recent activity has been detected on your website
Check out if Inhibrx Biosciences is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Inhibrx Biosciences
Compare insights from companies similar to Inhibrx Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Inhibrx Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Inhibrx Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Inhibrx Biosciences.
Inhibrx Biosciences financials insights
Gather financial insights about Inhibrx Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Debt
$20M
2020
Debt
$1M
Inhibrx Biosciences Tech Stack
A closer look at the technologies used by Inhibrx Biosciences
See more technologies
Most Recent Scoops
Earnings
Earnings, Finance
Person-Based
Award
Project
Inhibrx Biosciences has reported that Ozekibart demonstrated responses in colorectal cancer patients who had previously received irinotecan or FOLFIRI without response.
Medical Research, Pharmaceuticals
Project
Inhibrx Biosciences has highlighted that Ozekibart, a DR5 agonist with a unique tetrameric structure and four binding domains in close proximity, has demonstrated meaningful clinical activity beyond sarcoma in solid tumors including colorectal cancer, driven in part by synergy with irinotecan, which sensitizes tumor cells to DR5-mediated cell death.
Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals, Clinical Operations
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Inhibrx Biosciences
Sign Up For FreeTo access detailed company insights
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or m... Read More
